RU2409667C2 - Вирусоподобные частицы, включающие гибридный белок белка оболочки бактериофага ар205 и антигенного полипептида - Google Patents
Вирусоподобные частицы, включающие гибридный белок белка оболочки бактериофага ар205 и антигенного полипептида Download PDFInfo
- Publication number
- RU2409667C2 RU2409667C2 RU2007114956/10A RU2007114956A RU2409667C2 RU 2409667 C2 RU2409667 C2 RU 2409667C2 RU 2007114956/10 A RU2007114956/10 A RU 2007114956/10A RU 2007114956 A RU2007114956 A RU 2007114956A RU 2409667 C2 RU2409667 C2 RU 2409667C2
- Authority
- RU
- Russia
- Prior art keywords
- polypeptide
- seq
- modified
- antigen
- modified hpv
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title claims abstract 24
- 102000036639 antigens Human genes 0.000 title claims abstract 24
- 108091007433 antigens Proteins 0.000 title claims abstract 24
- 102000004169 proteins and genes Human genes 0.000 title claims abstract 9
- 108090000623 proteins and genes Proteins 0.000 title claims abstract 9
- 241001515965 unidentified phage Species 0.000 title claims abstract 5
- 239000002245 particle Substances 0.000 title claims abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 58
- 229920001184 polypeptide Polymers 0.000 title claims 52
- 102000004196 processed proteins & peptides Human genes 0.000 title claims 52
- 101710132601 Capsid protein Proteins 0.000 title claims 4
- 101710094648 Coat protein Proteins 0.000 title claims 4
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 title claims 4
- 101710125418 Major capsid protein Proteins 0.000 title claims 4
- 101710141454 Nucleoprotein Proteins 0.000 title claims 4
- 101710083689 Probable capsid protein Proteins 0.000 title claims 4
- 230000028993 immune response Effects 0.000 claims abstract 11
- 230000001939 inductive effect Effects 0.000 claims abstract 10
- 238000004519 manufacturing process Methods 0.000 claims abstract 5
- 239000000203 mixture Substances 0.000 claims abstract 5
- 206010020751 Hypersensitivity Diseases 0.000 claims abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 4
- 206010028980 Neoplasm Diseases 0.000 claims abstract 2
- 201000011510 cancer Diseases 0.000 claims abstract 2
- 201000010099 disease Diseases 0.000 claims abstract 2
- 208000035475 disorder Diseases 0.000 claims abstract 2
- 230000003308 immunostimulating effect Effects 0.000 claims 11
- 108020004707 nucleic acids Proteins 0.000 claims 11
- 102000039446 nucleic acids Human genes 0.000 claims 11
- 150000007523 nucleic acids Chemical class 0.000 claims 11
- 239000002773 nucleotide Substances 0.000 claims 9
- 125000003729 nucleotide group Chemical group 0.000 claims 9
- 239000012634 fragment Substances 0.000 claims 6
- 125000006850 spacer group Chemical group 0.000 claims 6
- 108020001507 fusion proteins Proteins 0.000 claims 5
- 102000037865 fusion proteins Human genes 0.000 claims 5
- 108700010900 influenza virus proteins Proteins 0.000 claims 5
- 108091034117 Oligonucleotide Proteins 0.000 claims 4
- 230000003834 intracellular effect Effects 0.000 claims 4
- 241001672158 Acinetobacter phage AP205 Species 0.000 claims 3
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims 3
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims 3
- 101800001586 Ghrelin Proteins 0.000 claims 3
- 102400000442 Ghrelin-28 Human genes 0.000 claims 3
- 241001465754 Metazoa Species 0.000 claims 3
- 208000030961 allergic reaction Diseases 0.000 claims 3
- 150000001413 amino acids Chemical group 0.000 claims 3
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 229960005486 vaccine Drugs 0.000 claims 3
- 102400000967 Bradykinin Human genes 0.000 claims 2
- 101800004538 Bradykinin Proteins 0.000 claims 2
- 102400000921 Gastrin Human genes 0.000 claims 2
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 claims 2
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 claims 2
- 102000004083 Lymphotoxin-alpha Human genes 0.000 claims 2
- 108090000542 Lymphotoxin-alpha Proteins 0.000 claims 2
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 claims 2
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims 2
- 108091008605 VEGF receptors Proteins 0.000 claims 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 claims 2
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 241000712461 unidentified influenza virus Species 0.000 claims 2
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 claims 2
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 1
- 108010064733 Angiotensins Proteins 0.000 claims 1
- 102000015427 Angiotensins Human genes 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims 1
- 102100036846 C-C motif chemokine 21 Human genes 0.000 claims 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 claims 1
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims 1
- 108010065524 CD52 Antigen Proteins 0.000 claims 1
- 241000282465 Canis Species 0.000 claims 1
- 241000606161 Chlamydia Species 0.000 claims 1
- 108020004705 Codon Proteins 0.000 claims 1
- 230000007064 DNA hydrolysis Effects 0.000 claims 1
- 108010061629 Dermatophagoides pteronyssinus antigen p 1 Proteins 0.000 claims 1
- 101150029707 ERBB2 gene Proteins 0.000 claims 1
- 102100023688 Eotaxin Human genes 0.000 claims 1
- 101710139422 Eotaxin Proteins 0.000 claims 1
- 241000282324 Felis Species 0.000 claims 1
- 108010052343 Gastrins Proteins 0.000 claims 1
- 241000711549 Hepacivirus C Species 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 claims 1
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 claims 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims 1
- 101001005719 Homo sapiens Melanoma-associated antigen 3 Proteins 0.000 claims 1
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 claims 1
- 102100026011 Interleukin-13 Human genes 0.000 claims 1
- 108090000176 Interleukin-13 Proteins 0.000 claims 1
- 102000013691 Interleukin-17 Human genes 0.000 claims 1
- 108050003558 Interleukin-17 Proteins 0.000 claims 1
- 102100039897 Interleukin-5 Human genes 0.000 claims 1
- 108010002616 Interleukin-5 Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 102000003959 Lymphotoxin-beta Human genes 0.000 claims 1
- 108090000362 Lymphotoxin-beta Proteins 0.000 claims 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 claims 1
- 102100025082 Melanoma-associated antigen 3 Human genes 0.000 claims 1
- 102000018697 Membrane Proteins Human genes 0.000 claims 1
- 108010052285 Membrane Proteins Proteins 0.000 claims 1
- 101710176384 Peptide 1 Proteins 0.000 claims 1
- 102000015731 Peptide Hormones Human genes 0.000 claims 1
- 108010038988 Peptide Hormones Proteins 0.000 claims 1
- 101000899004 Phasmahyla jandaia Des-Arg9-bradykinin Proteins 0.000 claims 1
- 102000015439 Phospholipases Human genes 0.000 claims 1
- 108010064785 Phospholipases Proteins 0.000 claims 1
- 241000223960 Plasmodium falciparum Species 0.000 claims 1
- 241000223821 Plasmodium malariae Species 0.000 claims 1
- 241001505293 Plasmodium ovale Species 0.000 claims 1
- 241000223810 Plasmodium vivax Species 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 101100225046 Schizosaccharomyces pombe (strain 972 / ATCC 24843) ecl2 gene Proteins 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 claims 1
- 241000223996 Toxoplasma Species 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 102000003425 Tyrosinase Human genes 0.000 claims 1
- 108060008724 Tyrosinase Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000013566 allergen Substances 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 239000003659 bee venom Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 108010004164 hepatitis B surface antigen presurface protein 1 Proteins 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 229940100602 interleukin-5 Drugs 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 244000000010 microbial pathogen Species 0.000 claims 1
- 239000000813 peptide hormone Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000004962 physiological condition Effects 0.000 claims 1
- 229940118768 plasmodium malariae Drugs 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 108091006084 receptor activators Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract 2
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/18011—Details ssRNA Bacteriophages positive-sense
- C12N2795/18111—Leviviridae
- C12N2795/18123—Virus like particles [VLP]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61130804P | 2004-09-21 | 2004-09-21 | |
| US60/611,308 | 2004-09-21 | ||
| EP05105229 | 2005-06-14 | ||
| EP05105229.8 | 2005-06-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2007114956A RU2007114956A (ru) | 2008-10-27 |
| RU2409667C2 true RU2409667C2 (ru) | 2011-01-20 |
Family
ID=46307785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007114956/10A RU2409667C2 (ru) | 2004-09-21 | 2005-09-21 | Вирусоподобные частицы, включающие гибридный белок белка оболочки бактериофага ар205 и антигенного полипептида |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20080292652A1 (https=) |
| EP (1) | EP1791870A1 (https=) |
| JP (1) | JP2008513035A (https=) |
| AU (1) | AU2005286475A1 (https=) |
| BR (1) | BRPI0516953A (https=) |
| CA (1) | CA2580208A1 (https=) |
| MX (1) | MX2007003171A (https=) |
| NZ (1) | NZ554387A (https=) |
| RU (1) | RU2409667C2 (https=) |
| WO (1) | WO2006032674A1 (https=) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2568872C1 (ru) * | 2014-10-15 | 2015-11-20 | Игорь Геннадьевич Сивов | Лекарственное средство для лечения вирусного гепатита с |
| RU2705301C2 (ru) * | 2012-02-16 | 2019-11-06 | Влп Терапьютикс, Ллк | Композиция вирусоподобных частиц |
| RU2852174C1 (ru) * | 2025-01-31 | 2025-12-04 | Федеральное государственное учреждение "Федеральный исследовательский центр "Фундаментальные основы биотехнологии" Российской академии наук" | Рекомбинантная вакцина против вируса гриппа а человека и способ ее получения |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7264810B2 (en) * | 2001-01-19 | 2007-09-04 | Cytos Biotechnology Ag | Molecular antigen array |
| DE60234375D1 (de) * | 2001-09-14 | 2009-12-24 | Cytos Biotechnology Ag | VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG |
| EP2338510A1 (en) * | 2002-07-19 | 2011-06-29 | Novartis Pharma AG | Vaccine compositions containing amyloid beta1-6 antigen arrays |
| CN1753687A (zh) | 2002-10-29 | 2006-03-29 | 科勒制药集团股份有限公司 | Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用 |
| AU2004224761A1 (en) | 2003-03-26 | 2004-10-07 | Cytos Biotechnology Ag | HIV-peptide-carrier-conjugates |
| US7959928B2 (en) | 2004-10-05 | 2011-06-14 | Cytos Biotechnology Ag | VLP-antigen conjugates and their uses as vaccines |
| AU2005298689A1 (en) | 2004-10-25 | 2006-05-04 | Cytos Biotechnology Ag | Gastric inhibitory polypeptide (GIP) antigen arrays and uses thereof |
| CN101193654A (zh) * | 2005-06-14 | 2008-06-04 | 赛托斯生物技术公司 | 抗原偶联物及其用途 |
| ES2310062B1 (es) | 2005-07-15 | 2009-11-13 | Bionostra, S.L. | Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones. |
| NZ566971A (en) | 2005-09-28 | 2011-06-30 | Cytos Biotechnology Ag | Vaccine containing a virus like particle linked with an interleukin-1 molecule |
| CA2636139A1 (en) * | 2005-12-14 | 2007-06-21 | Cytos Biotechnology Ag | Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity |
| AT503690A1 (de) * | 2006-06-09 | 2007-12-15 | Biomay Ag | Hypoallergene moleküle |
| US8541559B2 (en) | 2006-06-12 | 2013-09-24 | Cytos Biotechnology Ag | Process for producing aggregated oligonucleotides |
| AU2013204383B2 (en) * | 2006-06-12 | 2016-09-22 | Kuros Us Llc | Processes for packaging oligonucleotides into virus-like particles of RNA bacteriophages |
| US20090142362A1 (en) * | 2006-11-06 | 2009-06-04 | Avant Immunotherapeutics, Inc. | Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP) |
| US8586728B2 (en) | 2006-12-12 | 2013-11-19 | Cytos Biotechnology Ag | Oligonucleotides containing high concentrations of guanine monomers |
| EP2121007A1 (en) * | 2006-12-21 | 2009-11-25 | Cytos Biotechnology AG | Circular ccr5 peptide conjugates and uses thereof |
| CN101245110B (zh) * | 2007-02-16 | 2010-09-15 | 鲁南制药集团股份有限公司 | 重组中性粒细胞抑制因子和水蛭原嵌合蛋白及其药物组合物 |
| US20110262472A1 (en) * | 2008-04-22 | 2011-10-27 | Cytos Biotechnology Ag | Vaccine compositions for the treatment of dengue fever and uses thereof |
| WO2010122164A1 (en) | 2009-04-23 | 2010-10-28 | Cytos Biotechnology Ag | VIRUS-LIKE PARTICLES OF BACTERIOPHAGE φCB5 |
| NZ596058A (en) * | 2009-04-30 | 2013-08-30 | Cytos Biotechnology Ag | Influenza hemagglutinin compositions and uses thereof |
| CA2793580A1 (en) * | 2010-03-29 | 2011-10-06 | Novartis Ag | Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant |
| GB201121571D0 (en) * | 2011-12-15 | 2012-01-25 | Astrimmune Ltd | Compounds and uses thereof |
| CN104011080B (zh) | 2011-12-22 | 2017-10-20 | 弗·哈夫曼-拉罗切有限公司 | 用于真核细胞的全长抗体展示系统及其用途 |
| ES2736500T3 (es) | 2014-06-18 | 2020-01-02 | Morphosys Ag | Proteínas de fusión y usos de las mismas |
| CN104255335B (zh) * | 2014-08-24 | 2016-08-31 | 苗建军 | 一种吊放蔓用钳 |
| MA40824A (fr) * | 2014-10-22 | 2017-08-29 | Saiba Gmbh | Particules de cmv de type virus modifié |
| WO2016112921A1 (en) | 2015-01-15 | 2016-07-21 | University Of Copenhagen | Virus-like particle with efficient epitope display |
| EP3368068B1 (en) | 2015-10-30 | 2020-11-18 | University of Copenhagen | Virus like particle with efficient epitope display |
| EP3389693A4 (en) | 2015-12-18 | 2019-08-21 | Agilvax, Inc. | COMPOSITIONS AND METHODS RELATED TO XCT PEPTIDES |
| BR112018071965A2 (pt) * | 2016-04-27 | 2019-03-06 | Benchmark Animal Health Ltd | tratamento da dermatite atópica canina |
| CN112500456B (zh) * | 2020-12-02 | 2022-10-28 | 深圳赫兹生命科学技术有限公司 | 一种去势ap205病毒样颗粒亚单位疫苗 |
| US20220241400A1 (en) * | 2021-02-02 | 2022-08-04 | Provaxus, Inc. | Immunomodulation platform and methods of use |
| WO2022218928A1 (en) | 2021-04-12 | 2022-10-20 | Saiba AG | Modified virus-like particles of bacteriophage ap205 |
| US20240156937A1 (en) * | 2021-04-23 | 2024-05-16 | Unm Rainforest Innovations | Baceriophage virus-like particles vaccines for chlamydia trachomatis infections |
| CN114933639B (zh) * | 2022-05-05 | 2023-12-29 | 中国农业科学院兰州兽医研究所 | 非洲猪瘟病毒p72N抗原表位蛋白及其制备方法和用途 |
| CN115819623A (zh) * | 2022-12-12 | 2023-03-21 | 长春百克生物科技股份公司 | 一种重组病毒样颗粒疫苗组合物的制备及应用 |
| CN118684781A (zh) * | 2023-03-21 | 2024-09-24 | 深圳赫兹生命科学技术有限公司 | GnRH-VLP重组去势疫苗及其制备方法 |
| EP4737572A1 (en) * | 2023-06-29 | 2026-05-06 | Shenzhen Herz Life Science Technology Co., Ltd | Preparation method for castrating ap205 virus-like particle subunit vaccine |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020193565A1 (en) * | 1998-03-27 | 2002-12-19 | Stanley Margaret Anne | Antigen preparation and use |
| WO2003031466A2 (en) * | 2001-10-05 | 2003-04-17 | Cytos Biotechnology Ag | Angiotensin peptide-carrier conjugates and uses thereof |
| US7264810B2 (en) * | 2001-01-19 | 2007-09-04 | Cytos Biotechnology Ag | Molecular antigen array |
| US7128911B2 (en) * | 2001-01-19 | 2006-10-31 | Cytos Biotechnology Ag | Antigen arrays for treatment of bone disease |
| CA2492823A1 (en) * | 2001-09-14 | 2003-03-27 | Cytos Biotechnology Ag | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
| DE60234375D1 (de) * | 2001-09-14 | 2009-12-24 | Cytos Biotechnology Ag | VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG |
| ES2316628T3 (es) * | 2001-11-07 | 2009-04-16 | Cytos Biotechnology Ag | Disposicion ordenada de antigenos que comprende rankl para el tratamiento de enfermedades oseas. |
| AU2002363382B2 (en) * | 2001-11-07 | 2007-07-19 | Cytos Biotechnology Ag | Antigen arrays presenting IL-5, IL-3 or eotaxin for treatment of allergic eosinophilic diseases |
| BR0311995A (pt) * | 2002-06-20 | 2005-04-05 | Cytos Biotechnology Ag | Partìculas semelhantes a vìrus empacotadas para o uso como adjuvantes: método de preparação e uso |
| ES2431963T3 (es) * | 2002-07-05 | 2013-11-28 | Folia Biotech Inc. | Partícula viral adyuvante |
| US7138252B2 (en) * | 2002-07-17 | 2006-11-21 | Cytos Biotechnology Ag | Molecular antigen arrays |
-
2005
- 2005-09-21 MX MX2007003171A patent/MX2007003171A/es not_active Application Discontinuation
- 2005-09-21 US US11/663,350 patent/US20080292652A1/en not_active Abandoned
- 2005-09-21 EP EP05786887A patent/EP1791870A1/en not_active Withdrawn
- 2005-09-21 AU AU2005286475A patent/AU2005286475A1/en not_active Abandoned
- 2005-09-21 CA CA002580208A patent/CA2580208A1/en not_active Abandoned
- 2005-09-21 NZ NZ554387A patent/NZ554387A/en not_active IP Right Cessation
- 2005-09-21 BR BRPI0516953-4A patent/BRPI0516953A/pt not_active IP Right Cessation
- 2005-09-21 JP JP2007532893A patent/JP2008513035A/ja active Pending
- 2005-09-21 WO PCT/EP2005/054721 patent/WO2006032674A1/en not_active Ceased
- 2005-09-21 RU RU2007114956/10A patent/RU2409667C2/ru not_active IP Right Cessation
Non-Patent Citations (1)
| Title |
|---|
| VORONKOVA T. et al., "Chimeric bacteriophage fr virus-like particles harboring the immunodominant C-terminal region of hamster polyomavirus VP1 induce a strong VP1-specific antibody response in rabbits and mice". Viral Immunol. 2002; 15(4):627-43. * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2705301C2 (ru) * | 2012-02-16 | 2019-11-06 | Влп Терапьютикс, Ллк | Композиция вирусоподобных частиц |
| RU2568872C1 (ru) * | 2014-10-15 | 2015-11-20 | Игорь Геннадьевич Сивов | Лекарственное средство для лечения вирусного гепатита с |
| RU2852174C1 (ru) * | 2025-01-31 | 2025-12-04 | Федеральное государственное учреждение "Федеральный исследовательский центр "Фундаментальные основы биотехнологии" Российской академии наук" | Рекомбинантная вакцина против вируса гриппа а человека и способ ее получения |
Also Published As
| Publication number | Publication date |
|---|---|
| US20080292652A1 (en) | 2008-11-27 |
| NZ554387A (en) | 2009-09-25 |
| BRPI0516953A (pt) | 2008-09-30 |
| WO2006032674A1 (en) | 2006-03-30 |
| AU2005286475A1 (en) | 2006-03-30 |
| CA2580208A1 (en) | 2006-03-30 |
| MX2007003171A (es) | 2007-05-23 |
| EP1791870A1 (en) | 2007-06-06 |
| RU2007114956A (ru) | 2008-10-27 |
| JP2008513035A (ja) | 2008-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2409667C2 (ru) | Вирусоподобные частицы, включающие гибридный белок белка оболочки бактериофага ар205 и антигенного полипептида | |
| JP2008513035A5 (https=) | ||
| JP6824154B2 (ja) | 修飾エンベロープタンパク質ｅ３を含むウイルス様粒子 | |
| CN1193791C (zh) | 抗原的有序分子呈递,制备及使用的方法 | |
| Pumpens et al. | The true story and advantages of RNA phage capsids as nanotools | |
| AU2015335027B2 (en) | Modified virus-like particles of CMV | |
| AU2004223736B2 (en) | Melan-A peptide analogue-virus-like-particle conjugates | |
| US20100291109A1 (en) | Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity | |
| RU2003125363A (ru) | Молекулярный массив антигенов | |
| US20110097417A1 (en) | Melan-a-carrier conjugates | |
| KR20070058426A (ko) | 비-인간 ｔｎｆ-펩티드의 담체 콘쥬게이트의 의학적 용도 | |
| EA035378B1 (ru) | Вирусоподобная частица с эффективным экспонированием эпитопов | |
| Al-Barwani et al. | Antigen delivery by virus-like particles for immunotherapeutic vaccination | |
| JP7623282B2 (ja) | 融合によって修飾されたｃｍｖのウイルス様粒子 | |
| NZ555590A (en) | Compositions comprising a VLP and IL-15 protein | |
| WO2021016509A1 (en) | Malaria immunogen and methods for using same | |
| US20080019991A1 (en) | Carrier Conjugates Of Tnf-Peptides | |
| JP2007518762A (ja) | グレリン−担体結合体 | |
| WO2005108425A1 (en) | Il-23 p19 antigen array and uses thereof | |
| Toebes et al. | Preclinical development of highly effective and safe DNA vaccines directed against HPV 16 E6 and E7 | |
| WO2024091589A1 (en) | Malaria immunogen and methods for using same | |
| Chackerian et al. | Virus‐like particles as antigen scaffolds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20120922 |